Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 14/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019597 | 0.90 | MAP2 (0.45) | MAP2SIRT1PTGS2SIRT2SIRT3 | |
| SCHEMBL4018151 | 0.84 | ALDH1A1 (0.48) | — | |
| SCHEMBL4312843 | 0.79 | MAP2 (0.53) | MAP2SIRT1SIRT2SIRT3 | |
| SCHEMBL2351150 | 0.77 | MAP2 (0.45) | MAP2SIRT1PTGS2SIRT2SIRT3 | |
| SCHEMBL4311159 | 0.77 | MAP2 (0.51) | MAP2SIRT1PTGS2SIRT2SIRT3 | |
| SCHEMBL4322534 | 0.77 | MAP2 (0.51) | MAP2SIRT1SIRT2SIRT3 | |
| SCHEMBL4322592 | 0.76 | MAP2 (0.50) | MAP2SIRT1PTGS2SIRT2SIRT3 | |
| SCHEMBL4018149 | 0.75 | ALDH1A1 (0.48) | — | |
| SCHEMBL2346319 | 0.74 | MAP2 (0.46) | MAP2SIRT1PTGS2SIRT2SIRT3 | |
| SCHEMBL2347447 | 0.74 | MAP2 (0.59) | MAP2SIRT1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261496-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | MAP2 732/4885SIRT1 2309/4885PTGS2 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.